23andMe SPAC Presentation Deck

in M Cumulative Genotyped Customers Cumulative Subscribers $ in M Revenue Gross Margin % Consumer & Research Services Adjusted EBITDA Adjusted EBITDA Note: Fiscal year ends March 31. FY19A 7.8 $441 44% ($86) ($141) Financial Summary FY20A 9.8 $305 45% ($66) ($147) FY21E 11.2 0.1 $218 45% ($9) ($106) FY22E 12.6 0.7 $256 51% ($10) ($134) FY23E 14.3 1.6 $317 55% $26 ($109) FY24E 16.4 2.9 $400 58% $71 ($78) 23andMe Confidential and Proprietary Information 34

View entire presentation